Skip to main
VYGR
VYGR logo

Voyager Therapeutics (VYGR) Stock Forecast & Price Target

Voyager Therapeutics (VYGR) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 45%
Buy 40%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Voyager Therapeutics Inc is positioned for a positive financial outlook due to its innovative gene therapy platform TRACER, which has the potential to yield durable efficacy with a single administration and addresses significant unmet needs in neurological diseases. The company retains co-commercialization options for its key programs, which enhances its long-term revenue potential and could provide critical clinical validation of its technology in human trials. Moreover, the successful advancement of its robust pipeline, alongside an extended cash runway into mid-2027, allows Voyager to focus on developing compelling treatments, potentially creating substantial value for shareholders.

Bears say

Voyager Therapeutics exhibits a negative financial outlook primarily due to its inability to generate sales revenue, coupled with a reported net loss of ($1.13) per share, indicating significant financial challenges that may hinder future profitability. The company's reliance on the success of its gene therapy programs, particularly VY7523 and VY9323, carries substantial risks as they face competition from more advanced tau antibody programs and could fail to demonstrate the necessary efficacy in clinical trials. Additionally, potential delays or unfavorable regulatory decisions further compound the risks, as any setbacks in progress or approval could adversely impact revenue projections and overall valuation estimates.

Voyager Therapeutics (VYGR) has been analyzed by 20 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 40% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Voyager Therapeutics (VYGR) Forecast

Analysts have given Voyager Therapeutics (VYGR) a Buy based on their latest research and market trends.

According to 20 analysts, Voyager Therapeutics (VYGR) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Voyager Therapeutics (VYGR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.